Scientific deep-dive

KPV for Gut Inflammation and IBD: What the Mouse Colitis Studies Show

KPV, a fragment of alpha-MSH, is marketed for IBD and gut health, but the evidence is preclinical only: mouse colitis models and cell culture, with no human trial. It is not FDA-approved. A draft October 2026 HHS policy would not enforce against topical and oral 503A compounding.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
9 min read·11 citations

KPV — the tripeptide lysine-proline-valine — is the C-terminal fragment (residues 11–13) of α-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid neuropeptide with well-documented anti-inflammatory properties[1]. Marketed as a compounded peptide for gut health, inflammatory bowel disease (IBD), and skin inflammation, KPV has attracted genuine scientific interest for two reasons: it retains the anti-inflammatory activity of its parent hormone even when acting independently of classic melanocortin receptors, and it is actively transported into intestinal epithelial and immune cells by the PepT1 oligopeptide transporter — the same protein that absorbs di- and tripeptides from digested dietary protein[2]. That uptake mechanism is the scientific basis for oral gut-targeted delivery. The preclinical evidence is real: multiple mouse colitis studies show reduced colonic inflammation with KPV[3], placing it alongside BPC-157 as one of the few compounded peptides with a body of preclinical gut data. The honest bottom line, however, is that every published piece of evidence for KPV's gut and skin effects comes from mouse models or cell culture. No published human clinical trial of KPV for IBD, gut health, skin inflammation, or any other indication exists as of 2026. The legal picture did change. HHS announced on October 28, 2026 that it does not intend to bring enforcement action against 503A pharmacies compounding single-ingredient KPV acetate as a topical or oral product within ten conditions[10]. That is enforcement discretion, not FDA approval. HHS published the policy in the Federal Register on October 30, 2026 as a draft, non-binding policy with a two-week window for written comments; it is not a rule[11]. Our news report covers the announcement. Our KPV peptide guide covers the basics, and our explainer on the HHS 503A peptide policy covers the rules.

What is KPV? Origin and structure

α-MSH is a 13-amino-acid melanocortin hormone produced from proopiomelanocortin (POMC) in the pituitary and several peripheral tissues. It acts at melanocortin receptors (MC1R–MC5R) to regulate pigmentation, energy balance, and immune responses. The anti-inflammatory effects of α-MSH have been recognized for decades, and research progressively identified the C-terminal fragment — Lys (K) – Pro (P) – Val (V), residues 11–13 — as the core active anti-inflammatory sequence[1]. KPV is small enough to be straightforwardly synthesized and, critically, small enough to be a substrate for intestinal di/tripeptide transporters — giving it a gut-delivery advantage that the full 13-amino-acid α-MSH molecule lacks.

A key pharmacological feature of KPV is its ability to exert anti-inflammatory effects without obligate engagement of melanocortin receptors. In vitro studies in human keratinocyte cells showed that KPV (MSH 11–13) activates intracellular signaling pathways independently of the canonical MC1R-mediated cAMP cascade that full-length α-MSH uses[5]. This receptor-independent mechanism is thought to involve direct inhibition of intracellular inflammatory kinase cascades — including the NF-κB pathway — without requiring cell-surface receptor binding. This is consistent with the observation that KPV retains activity in cell types expressing low levels of melanocortin receptors.

Mechanism: NF-κB inhibition and PepT1-mediated uptake

The anti-inflammatory mechanism of KPV converges on the NF-κB transcription factor pathway, the master regulator of pro-inflammatory gene expression. In vitro work with the closely related C-terminal fragment GKPV (α-MSH 10–13) demonstrated that this sequence inhibits TNF-α-stimulated NF-κB activation in cell culture[4]. Downstream of NF-κB suppression, KPV reduces the transcription and secretion of pro-inflammatory cytokines including IL-1β, TNF-α, IL-6, and IL-8 — the same cytokine profile that is dysregulated in ulcerative colitis and Crohn's disease.

The PepT1 (SLC15A1) oligopeptide transporter provides the gut-delivery rationale. PepT1 is expressed on the apical surface of intestinal epithelial cells and on macrophages within the intestinal lamina propria; it normally imports di- and tripeptides produced from luminal protein digestion[2]. Because KPV is a tripeptide, it is a direct substrate for PepT1-mediated uptake. A key observation from Dalmasso et al. (2008) is that PepT1 expression is upregulated in inflamed intestinal tissue relative to healthy tissue[2] — creating a degree of pathology-targeted delivery. Once inside epithelial cells and macrophages, KPV can suppress intracellular NF-κB signaling without needing cell-surface receptor engagement. This combination of transporter-mediated entry and intracellular NF-κB inhibition is the core mechanistic case for KPV as an oral gut-inflammation agent.

Preclinical evidence: mouse colitis and IBD models

The body of preclinical evidence for KPV in gut inflammation is genuine but confined to animal models and cell culture. The studies below form the peer-reviewed foundation; all should be read as hypothesis-generating preclinical data, not as evidence of efficacy in humans. Like the immunomodulatory peptide thymosin alpha-1, KPV has an interesting mechanistic profile and multiple supportive animal studies — but no published human trial to validate the signal.

  • Kannengiesser et al. (2008) — the foundational mouse study — tested KPV in two murine IBD models: acute DSS (dextran sodium sulfate)-induced colitis and the IL-10 knockout mouse model of chronic colitis. KPV reduced macroscopic and histological colitis scores, lowered colonic pro-inflammatory cytokines (including TNF-α and IL-12), and attenuated NF-κB activation in colonic tissue[3]. Study type: animal (mouse). No human data.
  • Dalmasso et al. (2008) demonstrated in both intestinal cell lines and mouse models that PepT1 mediates KPV uptake into intestinal epithelial cells and macrophages, and that this uptake reduces intestinal inflammation markers. The study directly linked PepT1 transporter activity to KPV's anti-inflammatory effect and established that PepT1 is overexpressed in inflamed mucosa[2]. Study type: animal + in vitro.
  • Laroui et al. (2010) loaded KPV into polysaccharide hydrogel nanoparticles targeted to the colon. These nanoparticle-encapsulated KPV preparations reduced DSS-induced colitis in mice more effectively than free KPV, suggesting encapsulation protects the peptide from gastrointestinal proteolytic degradation and improves colonic delivery[6]. Study type: animal (mouse).
  • Viennois et al. (2016) showed that PepT1 plays a role in promoting colitis-associated colorectal cancer in a murine model, and that KPV delivered via the PepT1 pathway provided therapeutic benefit — reducing both inflammation and tumor development in the colitis-cancer model[7]. Study type: animal (mouse).
  • Xiao et al. (2017) developed hyaluronic acid (HA)-functionalized nanoparticles for oral KPV delivery. HA targets CD44 receptors, which are upregulated on colonic macrophages in inflamed tissue. HA-KPV nanoparticles reduced DSS-induced colitis in mice and outperformed unencapsulated KPV, demonstrating the translational challenge of delivering free tripeptides orally[8]. Study type: animal (mouse).
Summary of preclinical KPV evidence in gut inflammation — all studies are mouse or cell models.
StudyModelDeliveryKey findingStudy type
Kannengiesser et al. 2008[3]DSS colitis + IL-10 KO (mouse)Systemic / localReduced colitis score, pro-inflammatory cytokines, NF-κB activationAnimal (mouse)
Dalmasso et al. 2008[2]Mouse colitis + intestinal cell linesPepT1-mediated (cellular uptake)PepT1 transports KPV into intestinal cells; reduces inflammation; PepT1 upregulated in inflamed tissueAnimal + in vitro
Laroui et al. 2010[6]DSS colitis (mouse)Polysaccharide nanoparticles (oral/rectal)Encapsulated KPV outperforms free KPV; protects peptide from GI degradationAnimal (mouse)
Viennois et al. 2016[7]Colitis-associated cancer (mouse)PepT1-mediatedKPV reduces colitis-associated tumor development via PepT1 pathwayAnimal (mouse)
Xiao et al. 2017[8]DSS ulcerative colitis (mouse)Oral HA-functionalized nanoparticlesCD44-targeted oral delivery alleviates UC; superior to free KPVAnimal (mouse)

All KPV gut evidence is preclinical — no human trial exists

The mouse colitis studies above are scientifically credible and published in peer-reviewed gastroenterology journals (Gastroenterology, Inflammatory Bowel Diseases, Molecular Therapy, Cell & Molecular Gastroenterology and Hepatology). They demonstrate a real and reproducible anti-inflammatory signal in rodent models. However, mouse IBD models have a well-documented high failure-to-translation rate; many compounds that reduce murine colitis fail in human trials. No published human clinical trial of KPV for IBD, ulcerative colitis, Crohn's disease, gut health, or any indication exists as of 2026. The gap between the preclinical signal and human evidence is the central fact for anyone considering compounded KPV. By contrast, people with Crohn's or colitis asking about approved weight-loss drugs have human data to go on: a 2026 systematic review supports GLP-1 use in stable, well-controlled IBD.

KPV and skin inflammation: in vitro data only

KPV is also marketed in topical compounded formulations for skin inflammation, including eczema and psoriasis. The scientific basis here is even thinner than for gut health. Elliott et al. (2004) examined how α-MSH, the 11–13 fragment KPV, and ACTH signal in human keratinocyte cells in culture (in vitro)[5]. The study described intracellular signaling pathways that KPV activates in these cells — a meaningful mechanistic observation — but it was conducted entirely in cell culture, not in human skin, and did not test clinical endpoints. No human clinical trial of topical KPV for any dermatological indication has been published.

Delivery forms, compounding, and regulatory status

KPV is available from compounding pharmacies in three main forms: injectable (subcutaneous), topical cream or gel (for skin applications), and oral capsules. The oral form is most discussed for gut health, and the PepT1 mechanism provides a plausible scientific rationale — if KPV survives upper-GI degradation intact, it could be taken up by inflamed intestinal tissue via PepT1. The preclinical nanoparticle studies[6][8] were motivated precisely by the recognition that free KPV may be substantially degraded by intestinal peptidases before reaching the colon, which is why researchers developed encapsulated formulations. Standard compounded oral capsules are not nanoparticle formulations. Whether simple oral capsule delivery achieves relevant intestinal concentrations in humans has not been studied. That gap now has a regulatory side: the HHS policy covers KPV only in topical and oral forms (injectable KPV falls outside it), and for any oral peptide it expects the compounder to hold records showing that its particular formulation is adequately absorbed by mouth in humans[10]. For which routes the HHS policy covers and what the route evidence shows, see KPV capsules, cream or injection.

From a regulatory standpoint, KPV has never been FDA-approved for any human indication. It has no New Drug Application (NDA) and no known active Investigational New Drug (IND) application in the United States. A 2023 review of the melanocortin system in IBD noted the mechanistic interest of KPV and related fragments while acknowledging the absence of clinical translation[9]. According to the HHS policy’s Appendix B, KPV was in FDA’s Category 2 of nominated bulk substances from September 2023 until April 22, 2026; CDER, FDA’s drug center, advised keeping it off the 503A bulks list, but the Pharmacy Compounding Advisory Committee voted for listing it[10]. Under the interim policy announced October 28, 2026, HHS says it does not intend to bring enforcement action against a 503A pharmacy that compounds KPV acetate (molecular weight 402.5) for an individual patient’s prescription if the product contains KPV as its only active ingredient, the bulk powder comes from an FDA-registered manufacturer and carries a certificate of analysis that tests identity, purity, endotoxin, and contaminants, and serious adverse events are reported to FDA MedWatch[10]. Premixed blends that contain KPV are not covered, which includes injectable KPV in the KLOW blend. None of this amounts to FDA approval; compounded drugs still reach patients without FDA having assessed whether they are safe or effective. No standardized clinical protocol exists for dose, frequency, or treatment duration, and the policy sets none. For current compounding options, see our KPV provider page.

PepT1 upregulation: a disease-targeted delivery hypothesis

One genuinely interesting feature of the KPV story is the observation that PepT1 expression is upregulated in inflamed intestinal mucosa[2]. If this pattern holds in human IBD, it would mean that oral KPV is absorbed more efficiently into the gut cells that most need anti-inflammatory signals — a form of pathology-targeted delivery without engineering. This is a compelling hypothesis. Human intestinal PepT1 expression in IBD has been studied in biopsy samples, but the oral bioavailability and mucosal concentration of free KPV in human IBD patients has not been measured. The hypothesis has not been tested clinically.

Safety considerations

  • No human safety database: Because no published clinical trial of KPV has been conducted, there is no peer-reviewed human adverse-event record. Safety profiles from any individual use are anecdotal and uncontrolled.
  • Compounding quality risk: Compounded KPV carries the class risks of all compounded peptides — variable purity, potency, and sterility without FDA oversight. Anyone considering using KPV alongside other compounded peptides should review the published evidence on peptide stacking safety first.
  • Injectable route risks: Subcutaneous administration carries injection-site reactions, infection risk, and the theoretical risk of immune sensitization to a foreign peptide sequence.
  • Systemic NF-κB suppression: KPV's mechanism involves inhibiting NF-κB-driven immune signaling. Systemic suppression of NF-κB activity, if achieved at clinically meaningful levels, could theoretically impair host defense against infection or reduce immune surveillance of neoplastic cells. This concern has not been studied for KPV in humans.
  • No established dosing protocol: No peer-reviewed clinical study has established a safe or effective dose range for KPV in humans by any route. Doses in compounding practice are extrapolated from rodent studies using body-weight scaling, a method known to be unreliable for peptide pharmacokinetics across species.

Clinical bottom line

KPV is a biologically plausible anti-inflammatory tripeptide with a real — if entirely preclinical — evidence base in mouse colitis models. Its PepT1-mediated intestinal uptake mechanism and NF-κB inhibitory activity are scientifically grounded and published in respected gastroenterology journals. However, the translation gap between promising mouse IBD data and human benefit is well-documented across gastroenterology drug development, and KPV has not cleared that gap. It is not FDA-approved for any indication, is available only as an unregulated compounded preparation, and has no standardized dosing or monitoring protocol. Anyone using compounded KPV is doing so without clinical trial evidence to guide dose, route, duration, or patient selection — and without an established safety record in humans.

Frequently Asked Questions

KPV is a tripeptide — lysine (K), proline (P), valine (V) — that forms the C-terminal residues (positions 11–13) of α-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid neuropeptide derived from proopiomelanocortin (POMC). α-MSH has well-documented anti-inflammatory and immunomodulatory properties; research identified the 11–13 C-terminal fragment as the core anti-inflammatory active sequence. KPV retains this activity even without engaging melanocortin receptors and can be taken up into intestinal epithelial cells and macrophages via the PepT1 oligopeptide transporter.
No. A PubMed search as of mid-2026 returns no published randomized controlled trial — or any other interventional human study — of KPV for inflammatory bowel disease, ulcerative colitis, Crohn's disease, gut health, or any other indication. All published evidence for KPV's gut anti-inflammatory effects comes from mouse colitis models and cell culture experiments. There is no human pharmacokinetic study of oral KPV either.
KPV's primary mechanism involves inhibiting NF-κB activation in intestinal epithelial cells and macrophages, reducing downstream pro-inflammatory cytokines including IL-1β, TNF-α, IL-6, and IL-8. It reaches the interior of these cells via the PepT1 (SLC15A1) oligopeptide transporter, which is expressed on intestinal epithelial cells and is upregulated in inflamed intestinal tissue — providing a theoretical degree of disease-targeted delivery. Importantly, KPV can exert these effects without engaging cell-surface melanocortin receptors, acting through intracellular signaling pathways.
No. KPV has never been FDA-approved for any human indication. It has no published New Drug Application (NDA) and no known active Investigational New Drug (IND) application in the United States. In a draft, non-binding policy announced October 28, 2026, HHS says it does not intend to bring enforcement action against those 503A pharmacies that compound single-ingredient KPV acetate as a topical or oral product, provided they meet ten conditions, among them a prescription for a named patient and a certificate of analysis from an FDA-registered manufacturer. HHS is exercising discretion there, not approving anything, and injectable KPV, blends and 'research use only' products get no protection from it.
Compounded KPV is available in injectable (subcutaneous), topical, and oral capsule forms. For gut-health applications, oral capsules are most commonly marketed. The PepT1 transporter provides a plausible rationale for oral gut delivery — KPV as a tripeptide is a substrate for PepT1-mediated intestinal uptake. However, free oral KPV may be substantially degraded by gastrointestinal proteases before reaching the colon. Preclinical researchers addressed this limitation by developing nanoparticle-encapsulated formulations, which outperformed free KPV in mouse models. Standard compounded oral capsules are not nanoparticle formulations, and there is no human pharmacokinetic study confirming that oral KPV reaches therapeutic concentrations in inflamed human colon. Under the draft October 2026 HHS policy, only topical and oral KPV are covered, and an oral product needs documentation of adequate oral bioavailability in humans.
There is no published human safety data for KPV. Because no clinical trial has ever been conducted, there is no peer-reviewed adverse-event record, and any safety impression from individual use is anecdotal and uncontrolled. Compounded KPV also carries the class risks of all compounded peptides — variable purity, potency, and sterility without FDA oversight — and injectable forms add injection-site reactions and infection risk. Its NF-κB-inhibiting mechanism could in theory blunt normal immune defenses if it reaches meaningful systemic levels, though this has not been studied in humans. Anyone considering KPV for a gut or skin condition should consult a clinician rather than self-treat.
Both KPV and BPC-157 are compounded peptides marketed for gut inflammation, and both have supporting preclinical mouse-model evidence. Neither has a published human randomized controlled trial for gut health or IBD. KPV's distinguishing feature is its specific mechanism — PepT1-mediated uptake into intestinal tissue and intracellular NF-κB inhibition — with a more targeted scientific rationale for oral gut delivery and inflammation resolution. BPC-157 has a broader range of preclinical gut-injury models in its evidence base. Any comparison between them in human patients is not informed by clinical evidence.

References

  1. 1.Luger TA, Brzoska T. α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Review covering α-MSH C-terminal fragments including KPV; anti-inflammatory mechanisms and therapeutic applications. Ann Rheum Dis. 2007. PMID: 17934097.
  2. 2.Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Mouse and cell study; PepT1 actively transports KPV into intestinal epithelial cells and macrophages; inflammation reduced; PepT1 expression upregulated in inflamed intestinal tissue. Gastroenterology. 2008. PMID: 18061177.
  3. 3.Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. DSS colitis and IL-10 knockout mouse models; KPV reduced colitis scores, pro-inflammatory cytokines (TNF-α, IL-12), and NF-κB activation in colonic tissue. Inflamm Bowel Dis. 2008. PMID: 18092346.
  4. 4.Kelly JM, Moir AJ, Carlson K, Yang Y, MacNeil S, Haycock JW. Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity. In vitro; α-MSH C-terminal fragment GKPV inhibits TNF-α-driven NF-κB activation; mechanistic basis for NF-κB inhibition by C-terminal MSH peptides. Peptides. 2006. PMID: 16274845.
  5. 5.Elliott RJ, Szabo M, Wagner MJ, Kemp EH, MacNeil S, Haycock JW. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. In vitro (human keratinocyte cell culture); KPV activates intracellular anti-inflammatory signaling independently of the MC1R-mediated cAMP pathway. J Invest Dermatol. 2004. PMID: 15102092.
  6. 6.Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. KPV-loaded nanoparticles outperform free KPV in DSS mouse colitis; encapsulation protects peptide from GI degradation and enhances colonic delivery. Gastroenterology. 2010. PMID: 19909746.
  7. 7.Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M, Han MK, Garg P, Xiao B, Merlin D. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Mouse study; PepT1 promotes colitis-associated colorectal cancer; KPV via PepT1 reduces tumor development alongside inflammation. Cell Mol Gastroenterol Hepatol. 2016. PMID: 27458604.
  8. 8.Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mouse DSS colitis model; HA-functionalized nanoparticles target CD44+ colonic macrophages in inflamed tissue; superior anti-inflammatory effect vs. free KPV by oral route. Mol Ther. 2017. PMID: 28143741.
  9. 9.Gravina AG, Pellegrino R, Durante T, Palladino G, Imperio G, D'Amico G, Trotta MC, Dallio M, Romeo M, D'Amico M, Federico A. The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. 2023 review; covers MC receptors, α-MSH C-terminal fragments including KPV, and the gap between preclinical promise and absent clinical translation. Cells. 2023. PMID: 37508552.
  10. 10.U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A and Appendix B). HHS. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  11. 11.U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice; Docket No. HHS-OASH-2026-0496; FR Doc. 2026-22192. Federal Register. 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances

KPV Capsules, Cream or Injection? Route, Evidence and What the HHS Policy Covers

KPV capsules, creams and injections compared by route. The draft HHS 503A policy covers only topical and oral KPV, and oral forms need documented human bioavailability. What mouse and lab skin studies show, and why injectable KPV falls outside the policy.

9 min read

BPC-157 for Gut Health & Leaky Gut: What the Evidence Shows

BPC-157 is the most-studied peptide in gastrointestinal research — yet every controlled experiment is in rats. We map the NSAID-protection, colitis, fistula, and leaky-gut evidence alongside the human RCT gap.

9 min read

HHS Peptide Compounding Policy (2026): What It Allows for BPC-157 and 5 Others

In a draft, non-binding policy announced October 28, 2026, HHS says it does not intend to bring enforcement action against 503A pharmacies that compound BPC-157, TB-500, MOTS-c, KPV, semax or epitalon if ten conditions are met. Only single-ingredient products qualify.

11 min read

KLOW Peptide Blend (KPV, GHK-Cu, BPC-157, TB-500): Evidence and Legal Status

What is in the KLOW peptide blend (GHK-Cu, BPC-157, TB-500, KPV), what the evidence shows for each, why there is no established dose, and why the draft 2026 HHS compounding policy does not cover blends or GHK-Cu.

9 min read

Semax Nasal Spray: Evidence, Safety and Why HHS Allows Only the Intranasal Route

Semax nasal spray is the route behind nearly all human semax research, and the only one the draft HHS 503A policy covers. What small Russian studies show, what is unknown about safety, and why injectable semax and semax-selank sprays fall outside the policy.

9 min read

Semax vs Selank: Evidence, Differences and Which One the HHS Policy Covers

Semax and selank are related Russian peptides with different targets: semax studied in stroke, selank in anxiety. We compare their sequences, mechanisms and small human studies, and explain why only semax is covered by the draft 2026 HHS 503A compounding policy.

9 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.7

Ro

FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

Read full review →

From $149/mo

+ required membership

Get started →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $59/mo

+ required membership

Get started →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $79/mo

“starting at” price

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →